PART 01:Executive summary
PART 02:Scope of the report
PART 03:Market research methodology
PART 04:Introduction
PART 05:Plasma therapeutics: An overview:
Components of blood plasma
Process to derive plasma therapeutics
Clinical uses of plasma
Cost structure of plasma therapeutics
PART 06:Regulation of plasma therapeutics
Regulatory authorities
PART 07:Market landscape
Market overview
Market size and forecast
Five forces analysis
PART 08:Market segmentation by fractionation products of plasma
Human albumin
Plasma derived coagulation factors
Immunoglobulins
Hyperimmune globulins
A1PI
Global human albumin market 2014-2019
Global immunoglobulins market 2014-2019
Global A1PI market 2014-2019
PART 09:Market segmentation by disease type
Clotting disorders
Immune disorders
AATD
Others
PART 10:Geographical segmentation
PART 11:Market drivers
PART 12:Impact of drivers
PART 13:Market challenges
PART 14:Impact of drivers and challenges
PART 15:Market trends
PART 16:Vendor landscape
Competitive scenario
Market share analysis 2014
Other prominent vendors
PART 17:Key vendor analysis
Baxter International Inc.
CSL Behring
Grifols
Octapharma
PART 18:Appendix
List of abbreviation
[List of Exhibits]
Exhibit 01: Product offerings
Exhibit 02: Composition of blood
Exhibit 03: Composition of plasma
Exhibit 04: Total collection of plasma in US 2010-2014 (in liters)
Exhibit 05: Projected fractionation capacity of manufacturing units in US and EU (millions of liter/annum)
Exhibit 06: Process of procurement and manufacturing of plasma therapeutics
Exhibit 07: Regulatory policies of plasma protein therapy lifecycle
Exhibit 08: Global plasma therapeutics market 2014-2019 ($ billions)
Exhibit 09: Five forces analysis
Exhibit 10: Global plasma therapeutics market segment by fractionation products of plasma
Exhibit 11: Global human albumin market 2014-2019 ($ millions)
Exhibit 12: Key performance indicators of global albumin market
Exhibit 13: Global immunoglobulins market 2014-2019 ($ millions)
Exhibit 14: Key performance indicators of global immunoglobulin market
Exhibit 15: Global A1PI market 2014-2019 ($ millions)
Exhibit 16: Key performance indicators of global A1PI market
Exhibit 17: Global plasma therapeutics market segment by disease type
Exhibit 18: Segmentation of global plasma therapeutics market by geography 2014
Exhibit 19: Drivers of global plasma therapeutics market
Exhibit 20: Impact of drivers
Exhibit 21: Challenges of global plasma therapeutics market
Exhibit 22: Impact of drivers and challenges
Exhibit 23: Global plasma therapeutics market share analysis 2014
Exhibit 24: YoY growth and revenue generated by plasma therapeutics 2011-2014 ($ millions)
Exhibit 25: YoY growth and revenue generate 2011-2014 ($ millions)
Exhibit 26: YoY growth and revenue of bioscience division 2011-2014 ($ millions)
Exhibit 27: Share of revenue by different divisions in 2014
Exhibit 28: YoY growth and revenue of plasma therapeutics 2011-2014 ($ millions)
Exhibit 29: Baxter International Inc. : Business segmentation
Exhibit 30: Baxter International Inc.: Revenue by business segmentation 2013
Exhibit 31: Baxter International Inc.: Revenue by geographical segmentation 2013
Exhibit 32: CSL Behring: Therapeutic areas segmentation 2013
Exhibit 33: CSL Behring: Product portfolio
Exhibit 34: CSL Behring: Geographical segmentation by revenue 2013
Exhibit 35: Grifols: Business segmentation by revenue 2013
Exhibit 36: Grifols: Business segmentation by revenue 2012 and 2013 ($ billions)
Exhibit 37: Grifols: Geographical segmentation by revenue 2013
Exhibit 38: Octapharma: Product offerings
【掲載企業】
Baxter, CSL Behring, Grifols Therapeutics, Octapharma, Abeona Therapeutics, ADMA Biologics, Amag Pharmaceuticals, Antares Pharma, BioDelivery Sciences, Bio Products Laboratory, Biota Pharmaceuticals, Biotest Pharmaceuticals, China Biologic Products, Depomed, Emergent BioSolutions, Ethicon, Flamel Technologies, Kamada, Kedrion, King Pharmaceuticals, Nektar Therapeutics, OMRIX Biopharmaceuticals, ProMetic Life Sciences, Rockwell Medical, The Medicines, ZymoGenetics
【資料のキーワード】
血漿交換療法、アルブミン、免疫グロブリン、凝固因子、A1PI、治療、凝固障害、免疫異常症、AATD
【調査方法】
一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)